Holen Sie sich die Stockscreener-App
91.94
1.87%
-1.755
Handel nachbörslich:
91.94
0.005
+0.01%
Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten
3,000 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Purchased by Flower City Capital - MarketBeat
Zacks Research Issues Pessimistic Forecast for AXSM Earnings - MarketBeat
Axsome Asks FDA to Approve Questionable Alzheimer’s Agitation Drug - Being Patient
When Will Axsome Therapeutics, Inc. (NASDAQ:AXSM) Turn A Profit? - Simply Wall St
Axsome reports mixed results for Alzheimer's agitation drug - MSN
Analysts Set Axsome Therapeutics, Inc. (NASDAQ:AXSM) PT at $129.43 - MarketBeat
William Blair Has Positive Forecast for AXSM FY2024 Earnings - MarketBeat
William Blair Has Positive Estimate for AXSM FY2024 Earnings - MarketBeat
Axsome (AXSM) Moves 11.5% Higher: Will This Strength Last? - MSN
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Axsome’s 2024 Results Show Growth in Sunosi Sales and Progress for AXS-12 - Sleep Review
Pallas Capital Advisors LLC Purchases Shares of 26,435 Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Truist raises Axsome Therapeutics target to $180, maintains Buy By Investing.com - Investing.com Canada
Objective long/short (AXSM) Report - Stock Traders Daily
Axsome Therapeutics (NASDAQ:AXSM) Shares Up 5.3% After Analyst Upgrade - MarketBeat
Axsome Therapeutics' (AXSM) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Stock Price Expected to Rise, Truist Financial Analyst Says - MarketBeat
Axsome Therapeutics, Inc. Provides Preliminary Unaudited Total Product Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue - The Manila Times
Truist raises Axsome stock target to $180, maintains buy rating - Investing.com
Truist raises Axsome stock target to $180, maintains buy rating By Investing.com - Investing.com UK
JPMorgan Chase & Co. Raises Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
What is Zacks Research's Forecast for AXSM FY2024 Earnings? - MarketBeat
Excessive Daytime Sleepiness Clinical and Non-Clinical - openPR
Axsome Therapeutics (NASDAQ:AXSM) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Profit Outlook - Yahoo Finance
Axsome to seek approval of AXS-05 to treat agitation in... - Alzheimer's News Today
Axsome to lean on totality of data in Alzheimer’s agitation submission - BioCentury
Alzheimer’s Drug Study Yields Mixed Results. Wall Street Still Likes Axsome. - Barron's
Axsome Posts Mixed Phase III Data in Alzheimer’s Agitation, Plans FDA Filing - BioSpace
Axsome Therapeutics stock steady as Baird reiterates confidence in long-term prospects - Investing.com Canada
GLP-1 questions emerge for 2025 [Video] - AOL
Axsome shares boosted by strong Phase 3 outcomes and Buy rating reiteration - Investing.com Canada
These 13 Things Could Make You More Likely to Get Alzheimer's, According to Research - AOL
Short Interest in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Declines By 7.9% - MarketBeat
Leerink reiterates Outperform on Axsome stock despite FDA uncertainty for Auvelity - Investing.com Canada
Axsome Therapeutics (NASDAQ:AXSM) Price Target Lowered to $122.00 at Mizuho - MarketBeat
Axsome Therapeutics Remains A Buy Despite AXS-05’s Mixed Results (NASDAQ:AXSM) - Seeking Alpha
HC Wainwright Reiterates "Buy" Rating for Axsome Therapeutics (NASDAQ:AXSM) - MarketBeat
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results - Benzinga
Axsome’s Alzheimer’s drug shows promise in trials By Investing.com - Investing.com Nigeria
Axsome Aims for FDA Filing in Alzheimer’s Agitation Despite Mixed Bag of Phase 3 Data - MedCity News
Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's Agitation - Yahoo! Voices
Axsome Therapeutics Stock Tumbles As Alzheimer's Studies Reveal Mixed Results: Retail Sentiment Remains Bullish - MSN
Axsome Therapeutics (NASDAQ:AXSM) Shares Gap DownHere's Why - MarketBeat
Smart Money Is Betting Big In AXSM Options - Benzinga
Axsome to seek approval for Alzheimer's-related agitation drug despite mixed data - Reuters.com
Axsome's Alzheimer's drug shows promise in trials - Investing.com India
Alzheimer's Agitation Drug Trial Data Mixed - Newsmax
Expert Outlook: Axsome Therapeutics Through The Eyes Of 8 Analysts - Benzinga
Axsome Therapeutics (NASDAQ:AXSM) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Axsome's Alzheimer's drug shows promise in trials By Investing.com - Investing.com Canada
Axsome Therapeutics, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
0.65%
4.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):